Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2014

01.10.2014 | Research Article

Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl-2 via microRNA let-7a and miR-34b in ovarian cancer cells

verfasst von: Y. L. Xie, Y. J. Yang, C. Tang, H. J. Sheng, Y. Jiang, K. Han, L. J. Ding

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study evaluated the effect of estrogen (E2), progesterone (P4), and the combination of them (E2 + P4) on survival rate, apoptosis, and the expressions of Bcl-2, hsa-let-7a and has-miR-34b in primary ovarian cancer cells to provide new clues for the clinical treatments of ovarian cancer.

Methods

The primary ovarian cancer cells from 60 cases of clinical ovarian cancer tissues were isolated and then cultured. The survival rate of ovarian cancer cells after the treatment of E2, P4 and E2 + P4 was analyzed by MTT assay. Cell apoptosis rate and cell cycle were measured by FACS analysis. Moreover, the relative abundance of Bcl-2 and microRNAs (let-7a, miR-34b) expressions were detected by quantitative real-time PCR (qRT-PCR) and Western blotting.

Results

Low concentrations of estrogen (10−10, 10−8, 10−6 mol/L) did not affect the proliferation of ovarian cancer cells. However, the high concentration of estrogen (10−4 mol/L) inhibited survival rate of ovarian cancer cells. Progesterone (10−4 mol/L) inhibited the proliferation of cancer cells. The combination of estrogen and progesterone significantly inhibited the survival rate of ovarian cancer cells with a time- and dose-dependent manner. High concentration of estrogen combined with progesterone (E2 + P4) induced apoptosis of ovarian cancer cells. E2 + P4 promoted the expression of let-7a and miR-34b and reduced the expression of Bcl-2 in ovarian cancer cells. When the expression of let-7a or/and miR-34b was inhibited using miRNA inhibitors, E2 + P4 treatment did not change the protein level of Bcl-2.

Conclusion

E2 + P4 significantly inhibited the cell survival, promoted the cell apoptosis, induced the expression of let-7a and miR-34b, and reduced the expression of Bcl-2 in ovarian cancer cells.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update. 2007;2:143–62. Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update. 2007;2:143–62.
2.
Zurück zum Zitat Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates anti-apoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology. 2001;142(6):2351–60.PubMed Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates anti-apoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology. 2001;142(6):2351–60.PubMed
3.
Zurück zum Zitat Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, et al. Estradiol-induced ezrin over-expression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett. 2005;220(1):57–65.PubMedCrossRef Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, et al. Estradiol-induced ezrin over-expression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett. 2005;220(1):57–65.PubMedCrossRef
4.
Zurück zum Zitat Yousef GM, Fracchioli S, Scorilas A, Borgoño CA, Iskander L, Puopolo M, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol. 2003;119(3):346–55.PubMedCrossRef Yousef GM, Fracchioli S, Scorilas A, Borgoño CA, Iskander L, Puopolo M, et al. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol. 2003;119(3):346–55.PubMedCrossRef
5.
Zurück zum Zitat Hinkula M, Pukkala E, Kyyrönen P, Kauppila A. Incidence of ovarian cancer of grand multiparous women–a population-based study in Finland. Gynecol Oncol. 2006;103(1):207–11.PubMedCrossRef Hinkula M, Pukkala E, Kyyrönen P, Kauppila A. Incidence of ovarian cancer of grand multiparous women–a population-based study in Finland. Gynecol Oncol. 2006;103(1):207–11.PubMedCrossRef
6.
Zurück zum Zitat Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer Clin. 2011;61(3):183–203.CrossRef Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer Clin. 2011;61(3):183–203.CrossRef
7.
Zurück zum Zitat Nguyen H, Syed V. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species. Gynecol Endocrinol. 2010;3:1473–7. Nguyen H, Syed V. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species. Gynecol Endocrinol. 2010;3:1473–7.
8.
Zurück zum Zitat Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int Gynecol Cancer. 2007;17(2):325–38.CrossRef Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int Gynecol Cancer. 2007;17(2):325–38.CrossRef
9.
Zurück zum Zitat Zheng W, Lu JJ, Luo F, Zheng Y, Feng Yj, Felix JC, et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76(1):80–8. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Yj, Felix JC, et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76(1):80–8.
10.
Zurück zum Zitat Veenhof CH, van der Burg ME, Nooy M, Aalders JG, Pecorelli S, Oliveira CF, et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur Cancer. 1994;30(5):697–8.CrossRef Veenhof CH, van der Burg ME, Nooy M, Aalders JG, Pecorelli S, Oliveira CF, et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur Cancer. 1994;30(5):697–8.CrossRef
11.
Zurück zum Zitat Nakano H, Yamada Y, Miyazawa T, Yoshida T. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int Oncol. 2013;42(6):1875–82. Nakano H, Yamada Y, Miyazawa T, Yoshida T. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int Oncol. 2013;42(6):1875–82.
12.
Zurück zum Zitat Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair. 2013;12(6):394–402.PubMedCrossRef Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A. Identification of miRNA modulators to PARP inhibitor response. DNA Repair. 2013;12(6):394–402.PubMedCrossRef
13.
Zurück zum Zitat Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8.PubMedCrossRef Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8.PubMedCrossRef
14.
Zurück zum Zitat Cho KR. Lessons from morphology, molecules and mice. Arch Pathol Lab Med, Ovarian cancer update. 2009;133:1775–81. Cho KR. Lessons from morphology, molecules and mice. Arch Pathol Lab Med, Ovarian cancer update. 2009;133:1775–81.
15.
Zurück zum Zitat Ziebarth AJ, Landen CN Jr, Alvarez RD. Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol. 2012;55(1):156–72.PubMedCrossRef Ziebarth AJ, Landen CN Jr, Alvarez RD. Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol. 2012;55(1):156–72.PubMedCrossRef
17.
Zurück zum Zitat Suh DH, Kim K, Kim JW. Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol. 2011;23(1):53–64.CrossRef Suh DH, Kim K, Kim JW. Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol. 2011;23(1):53–64.CrossRef
18.
Zurück zum Zitat Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology. 2004;15(1):100–4.PubMedCrossRef Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology. 2004;15(1):100–4.PubMedCrossRef
19.
Zurück zum Zitat Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001;285:1460–5.PubMedCrossRef Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001;285:1460–5.PubMedCrossRef
20.
Zurück zum Zitat Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002;94(7):497–504.PubMedCrossRef Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002;94(7):497–504.PubMedCrossRef
21.
Zurück zum Zitat Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, et al. Bcl-2 and p53 protein expression, apoptosis and p53 mution in human epithelial ovarian cancer. Am Pathol. 2000;156:409–17.CrossRef Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, et al. Bcl-2 and p53 protein expression, apoptosis and p53 mution in human epithelial ovarian cancer. Am Pathol. 2000;156:409–17.CrossRef
22.
Zurück zum Zitat Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.PubMedCrossRef Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.PubMedCrossRef
23.
Zurück zum Zitat Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8.PubMedCrossRef Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8.PubMedCrossRef
24.
Zurück zum Zitat Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, et al. Dysregulated microRNAs and their predicted targets associated with endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 2009;124:1358–65.PubMedCrossRef Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, et al. Dysregulated microRNAs and their predicted targets associated with endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 2009;124:1358–65.PubMedCrossRef
25.
Zurück zum Zitat Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, et al. MiR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer’s disease, inhibits bcl2 translation. Brain Res Bull. 2009;80:268–73.PubMedCrossRef Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, et al. MiR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer’s disease, inhibits bcl2 translation. Brain Res Bull. 2009;80:268–73.PubMedCrossRef
26.
Zurück zum Zitat Foekenes JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Pro Nat Acad Sci. 2008;105(35):13021–6.CrossRef Foekenes JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Pro Nat Acad Sci. 2008;105(35):13021–6.CrossRef
27.
Zurück zum Zitat Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007;6:2585–90.PubMedCrossRef Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007;6:2585–90.PubMedCrossRef
28.
Zurück zum Zitat Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA. 2007;27:11400–5.CrossRef Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA. 2007;27:11400–5.CrossRef
29.
Zurück zum Zitat Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.PubMedCrossRef Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–86.PubMedCrossRef
Metadaten
Titel
Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl-2 via microRNA let-7a and miR-34b in ovarian cancer cells
verfasst von
Y. L. Xie
Y. J. Yang
C. Tang
H. J. Sheng
Y. Jiang
K. Han
L. J. Ding
Publikationsdatum
01.10.2014
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1166-x

Weitere Artikel der Ausgabe 10/2014

Clinical and Translational Oncology 10/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.